Briefing

From Office of Health Economics
Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).

Access Statistics for this working paper series.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

000300: Immunisation for Everyone – The Polio Experience

Office of Health Economics

000298: Cost of the NHS

Office of Health Economics

000281: Health Care Research Expenditure

Office of Health Economics

000279: Accidents

Office of Health Economics

000278: Viral Hepatitis in Britain

Office of Health Economics

000269: The Faces of Regulation: Profit and Price Regulation of the UK Pharmaceutical Industry after the 1998 Competition Act

Jorge Mestre-Ferrandiz

000267: Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds

Adrian Towse

000261: Murder, Manslaughter and Infanticide

Office of Health Economics

000253: Infant and Child Health

Office of Health Economics

000252: Accidental deaths

Office of Health Economics

000249: Venereal Diseases

Office of Health Economics

000248: NHS Reorganisation

Office of Health Economics

000247: Parkinson's Disease

Office of Health Economics

000246: Benefits and Risks and Medical Care: a Symposium Held by the Office of Health Economics

David Taylor

000245: Estimating Pharmaceutical Companies' Value to the Nation: Case Study of the British Pharma Group

Martina Garau

000242: The Ideas and Influence of Alan Williams: Be Reasonable – Do It My Way

Anne R. Mason;Adrian Towse

000241: Sixty Years of the NHS: Changes in Demographics, Expenditure, Workforce and Family Services

Emma Hawe

000240: Health Care Services and the Single European Market

Diane Dawson;Lyndsay Mountford

000239: Challenges and Opportunities for Improving Benefit-Risk Assessment of Pharmaceuticals from an Economic Perspective

James T. Cross;Lou Garrison

000238: The Market for Biosimilars: Evolution and Policy Options

Adrian Towse

000237: New Guidelines for Economic Evaluation in Germany and the United Kingdom: Are We Any Closer to Developing International Standards?

Michael F. Drummond;Frans Rutten

000233: The Impact of Health Technology Assessment on Drug Development

Nancy Mattison

000232: American Exceptionalism and American Health Care: Implications for the US Debate on Cost-Effectiveness Analysis

Peter J. Neumann

000231: Deliberative Processes in Decisions about Health Care Technologies

Anthony Culyer

000230: How Fair? Competition between Independent and NHS Providers to Supply Non-Emergency Hospital Care to NHS Patients in England

Office of Health Economics

000228: Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?

Magnus Johannesson

000227: Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries

Martina Garau

000143: Causes of Death: A Study of a Century of Change in England and Wales

Lesley Cockcroft;Emma Hawe